RxDoctor Payments Data

Pamela Tuck, MD

Family Medicine · Montgomery, ALNPI 1720048275

Payments from drug & device makers

$13,005in general payments, 2019–2025

Across 774 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$1K
  • AbbVie$1K
  • Lilly USA, LLC$990
  • Pfizer$970
  • Johnson & Johnson$610
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$12,83399%
  • Education$1721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,005 in reported general payments places this provider in the 90th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$51,014
Medicare patients
138
Services billed
885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide183$218,680
TrulicityDulaglutide146$174,307
JardianceEmpagliflozin99$115,497
MounjaroTirzepatide102$110,612
LinzessLinaclotide108$75,229
EliquisApixaban83$69,926
JanuviaSitagliptin Phosphate59$61,251
RybelsusSemaglutide46$56,688
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$43,002
MyrbetriqMirabegron52$33,539
FarxigaDapagliflozin Propanediol39$29,432
XareltoRivaroxaban29$28,273
JanumetSitagliptin Phos/Metformin Hcl13$19,885
Repatha SureclickEvolocumab35$18,395
GemtesaVibegron14$15,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$990$284,919248 claims
Novo NordiskOzempic, Rybelsus$1,507$275,368229 claims
Boehringer IngelheimJardiance$506$115,49799 claims
AbbVieLinzess, Namzaric$1,044$83,878121 claims
MerckJanuvia, Janumet$351$81,13672 claims
PfizerEliquis$970$69,92683 claims
GSKTrelegy Ellipta, Breo Ellipta$1,287$50,34954 claims
AstraZenecaFarxiga, Symbicort$571$35,75966 claims
Astellas Pharma US IncMyrbetriq$452$33,53952 claims
Johnson & JohnsonXarelto$610$28,27329 claims
Sumitomo Pharma America, Inc.Gemtesa$130$15,79414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →